Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) today announced that
AstraZeneca (LSE/STO/Nasdaq: AZN) presented interim results from
the randomized NeoCOAST-2 (NCT05061550) Phase 2 platform study
during the 2024 World Conference on Lung Cancer on September 8,
2024.
The NeoCOAST-2 platform study is intended to assess the safety
and efficacy of neoadjuvant durvalumab alone or combined with novel
agents and chemotherapy in resectable, early-stage non-small cell
lung cancer (NSCLC), followed by adjuvant treatment with durvalumab
with or without the novel agents. The preliminary data of three
arms were presented at WCLC, namely:
- Arm 1: oleclumab in combination with durvalumab and platinum
doublet chemotherapy in the neoadjuvant setting and durvalumab plus
oleclumab in the adjuvant setting;
- Arm 2: monalizumab in combination with durvalumab and platinum
doublet chemotherapy in the neoadjuvant setting and durvalumab plus
monalizumab in the adjuvant setting and;
- Arm 4: datopotamab deruxtecan in combination with durvalumab
and single agent platinum chemotherapy in the neoadjuvant setting,
and durvalumab alone in the adjuvant setting.
In this preliminary analysis on the first 60 of 72 patients
randomized to Arm 2, monalizumab added to durvalumab plus
platinum-based chemotherapy doublet induced a pathological complete
response rate of 26.7% [95% CI; 16.1–39.7] and a major pathological
response rate of 53.3% [95% CI; 40.0–66.3] which are numerically
higher than the durvalumab plus platinum doublet approved regimen.
Treatment in Arm 2 showed manageable safety profile and no impact
on surgical rate.
The presentation will be available on Innate’s website, in the
publications section.
“We’re pleased to see the preliminary results from the
NeoCOAST-2 Phase 2 trial presented at WCLC and the encouraging
clinical outcomes for patients with early-stage non-small cell lung
cancer across all treatment arms,” said Dr Sonia Quaratino,
Chief Medical Officer of Innate Pharma. “Monalizumab is the
first checkpoint inhibitor targeting the inhibitory receptor NKG2A
on NK cells and CD8 T cells. Based on these preliminary results, we
remain excited about the potential of extending the clinical
benefit of durvalumab in the neoadjuvant/adjuvant setting with the
addition of monalizumab in patients with non-small cell lung
cancer. We look forward to the final analysis and the translation
of these preliminary data to Event Free Survival (EFS) data in due
course.”
About NSCLC:
In 2022, an estimated 2.5 million people were diagnosed with
lung cancer worldwide1. Lung cancer is broadly split into NSCLC and
small cell lung cancer, with 80-85% classified as NSCLC2,3,4 Stage
III NSCLC represents approximately one quarter of NSCLC
incidence5.
Stage III (locally advanced) NSCLC is commonly divided into
three subcategories (IIIA, IIIB and IIIC), defined by how much the
cancer has spread locally.
About Monalizumab
Monalizumab is a potentially first-in-class immune checkpoint
inhibitor targeting NKG2A receptors expressed on tumor infiltrating
cytotoxic CD8+ T cells and NK cells.
NKG2A is an inhibitory checkpoint receptor for HLA-E. By
expressing HLA-E, cancer cells can protect themselves from killing
by NKG2A+ immune cells. HLA-E is frequently overexpressed in the
cancer cells of many solid tumors and hematological malignancies.
Monalizumab may reestablish a broad anti-tumor response mediated by
NK and T cells and may enhance the cytotoxic potential of other
therapeutic antibodies6.
AstraZeneca obtained full oncology rights to monalizumab in
October 2018 through a co-development and commercialization
agreement initiated in 2015. The ongoing development for
monalizumab is focused on investigating monalizumab in various
combination strategies in NSCLC and other malignancies.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through therapeutic antibodies and its ANKET®
(Antibody-based NK cell Engager
Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, as well as ANKET® multi-specific NK
cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on LinkedIn and X.
Information about Innate Pharma shares
ISIN code Ticker
code LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts and the Company’s continued
ability to raise capital to fund its development. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website (http://www.amf-france.org) or on Innate Pharma’s
website (www.innate-pharma.com), and public filings and reports
filed with the U.S. Securities and Exchange Commission (“SEC”),
including the Company’s Annual Report on Form 20-F for the year
ended December 31, 2023, and subsequent filings and reports filed
with the AMF or SEC, or otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
1 Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L,
Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer
Observatory: Cancer Today. Lyon, France: International Agency for
Research on Cancer. Available from:
https://gco.iarc.who.int/today
2 Provencio M, et al. Inoperable Stage III Non-Small Cell Lung
Cancer: Current Treatment and Role Of Vinorelbine. J Thorac Dis.
2011;3:197-204
3 Cheema PK, et al. Perspectives on Treatment Advances for Stage
III Locally Advanced Unresectable Non-Small-Cell Lung Cancer. Curr
Oncol. 2019;26(1):37–42.
4 LUNGevity Foundation. Types of Lung Cancer. Available at
https://lungevity.org/for-patients-caregivers/lung-cancer-101/types-of-lung-cancer.
Accessed September 2021.
5 EpiCast Report: NSCLC Epidemiology Forecast to 2025.
GlobalData. 2016.
6 André et al, Cell 2018
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240908660298/en/
For additional information, please contact:
Investors Innate Pharma Henry
Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Innate Pharma (EU:IPH)
過去 株価チャート
から 10 2024 まで 11 2024
Innate Pharma (EU:IPH)
過去 株価チャート
から 11 2023 まで 11 2024
